Top

Reviews in Endocrine and Metabolic Disorders

Published in:

28-11-2023 | Thyroidectomy

Dynamic risk assessment in patients with differentiated thyroid cancer

Authors: Erika Abelleira, Fernando Jerkovich

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2024

Abstract

The current approach for patients with differentiated thyroid carcinoma should be individualized according to the risk of recurrence, and this stratification could be used to identify the risk of persistent/recurrent disease in three scenarios: preoperatively, immediately postoperatively, and during long-term follow-up. The initial risk of recurrence will tailor the management of the patient in the preoperative and immediate postoperative settings, while the dynamic risk, which considers the responses to treatment, could guide the decision-making process for remnant ablation and long-term management.

This review provides a summary of the existing information regarding the dynamic risk of recurrence and recommended management for patients with differentiated thyroid cancer. The application of this approach is essential to avoid unnecessary treatments for most patients who will have a favorable prognosis. On the other hand, it allows specific therapeutic interventions for those patients at high risk of recurrence. In the future, analysis of tumor biology and prospective studies will surely improve the accuracy of recurrence risk prediction.

Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-Cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375:614–7. https://doi.org/10.1056/NEJMp1604412.CrossRefPubMed

Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid Cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–48. https://doi.org/10.1001/jama.2017.2719.CrossRefPubMedPubMedCentral

Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid Cancer: from detection to final Follow-Up. J Clin Endocrinol Metab. 2019;104:4087–100. https://doi.org/10.1210/jc.2019-00177.CrossRefPubMedPubMedCentral

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26:1–133.PubMedPubMedCentralCrossRef

Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab. 2018;13:77–85. https://doi.org/10.1080/17446651.2018.1449641.CrossRefPubMedPubMedCentral

Bojoga A, Koot A, Bonenkamp J, de Wilt J, IntHout J, Stalmeier P, Hermens R, Smit J, Ottevanger P, Netea-Maier R. The impact of the extent of Surgery on the long-term outcomes of patients with low-risk differentiated non-medullary thyroid Cancer: a systematic Meta-analysis. J Clin Med. 2020;9:2316. https://doi.org/10.3390/jcm9072316.CrossRefPubMedPubMedCentral

Matsuura D, Yuan A, Harris V, Shaha AR, Tuttle RM, Patel SG, Shah JP, Ganly I. Surgical Management of Low-/Intermediate-Risk Node negative thyroid Cancer: a single-Institution Study using propensity matching analysis to compare thyroid lobectomy and total thyroidectomy. Thyroid. 2022;32:28–36. https://doi.org/10.1089/thy.2021.0356.CrossRefPubMedPubMedCentral

Jerkovich F, Cavallo A, Fassi J, Guerra J, Zund S, Neguerela MC, Faure E, Bielski L, Reyes A, Brenta G, Pitoia F. Lobectomy for low and low-intermediate-risk of recurrence differentiated thyroid cancer: multicentric study from Argentina. In: Latin American Thyroid Congress; April 20 to 23, 2023; Curitiba, Brazil:117023.

Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of Complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844–52. https://doi.org/10.1245/s10434-014-3846-8.CrossRefPubMed

10.

Smulever A, Pitoia F. High rate incidence of post-surgical adverse events in patients with low-risk papillary thyroid cancer who did not accept active surveillance. Endocrine. 2020;69:587–95. https://doi.org/10.1007/s12020-020-02310-8.CrossRefPubMed

11.

Mirghani H, Altedlawi Albalawi. IA 2nd. The Ongoing Debate regarding Completion Thyroidectomy Versus primary thyroid Surgery for low and intermediate differentiated thyroid carcinoma: a Meta-analysis. Cureus. 2020;12:e12033. https://doi.org/10.7759/cureus.12033.CrossRefPubMedPubMedCentral

12.

Li Z, Qiu Y, Fei Y, Xing Z, Zhu J, Su A. Prevalence of and risk factors for hypothyroidism after hemithyroidectomy: a systematic review and meta-analysis. Endocrine. 2020;70:243–55. https://doi.org/10.1007/s12020-020-02410-5.CrossRefPubMed

13.

Lee SJ, Song CM, Ji YB, Choi YY, Sohn YS, Park JH, Kim DS, Tae K. Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma. Langenbecks Arch Surg. 2021;406:1223–31. https://doi.org/10.1007/s00423-021-02189-7.CrossRefPubMed

14.

Dou Y, Chen Y, Hu D, Su X. The recovery of thyroid function in low-risk papillary thyroid Cancer after Lobectomy: a 3-Year Follow-Up study. Front Endocrinol (Lausanne). 2021;11:619841. https://doi.org/10.3389/fendo.2020.619841.CrossRefPubMed

15.

Cox C, Bosley M, Southerland LB, Ahmadi S, Perkins J, Roman S, Sosa JA, Carneiro-Pla D. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? Surgery. 2018;163:75–80. https://doi.org/10.1016/j.surg.2017.04.039.CrossRefPubMed

16.

Lee MC, Kim MJ, Choi HS, Cho SW, Lee GH, Park YJ, Park DJ. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid Cancer. Endocrinol Metab (Seoul). 2019;34:150–7. 103803/EnM.2019.34.2.150.PubMedCrossRef

17.

Xu S, Huang Y, Huang H, Zhang X, Qian J, Wang X, Xu Z, Liu S, Liu J. Optimal serum Thyrotropin Level for patients with papillary thyroid Carcinoma after Lobectomy. Thyroid. 2022;32:138–44. https://doi.org/10.1089/thy.2021.0404.CrossRefPubMed

18.

Lang BH, Wong CKH. Lobectomy is a more cost-effective option than total thyroidectomy for 1 to 4 cm papillary thyroid carcinoma that do not possess clinically recognizable high-risk features. Ann Surg Oncol. 2016;23:3641–52. https://doi.org/10.1245/s10434-016-5280-6.CrossRefPubMed

19.

Pitoia F, Smulever A. Vigilancia Activa Encubierta Y Los costos de la ausencia de implementación de la cirugía diferida en Argentina. Rev Argent Endocrinol Metab. 2020;57(3):1–10.

20.

Landry V, Siciliani E, Henry M, Payne RJ. Health-Related Quality of Life following total thyroidectomy and lobectomy for differentiated thyroid carcinoma: a systematic review. Curr Oncol. 2022;29:4386–422. https://doi.org/10.3390/curroncol29070350.CrossRefPubMedPubMedCentral

21.

Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, Schulte T. Quality of life in patients with thyroid cancer compared with the general population. Thyroid. 2012;22:117–24. https://doi.org/10.1089/thy.2011.0139.CrossRefPubMed

22.

NCCN clinical practice guidelines in oncology (NCCN Guidelines). : thyroid carcinoma—version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed April 25, 2018.

23.

Cooper DS, Doherty GM, Haugen BR, Kloss RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. https://doi.org/10.1089/thy.2009.0110.CrossRefPubMed

24.

Cooper DS, Doherty GM, Haugen BR, Kloss RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Sherman SI, Tuttle RM, American Thryoid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42. https://doi.org/10.1089/thy.2006.16.109.CrossRefPubMed

25.

Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007; 246:375–381. doi: 20.1097/SLA.0b013e31814697d9.

26.

In H, Bilimoria KY, Stewart AK, Wroblewsli KE, Posner MC, Talamonti MS, Winchester DP. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21:1520–9. https://doi.org/10.1245/s10434-014-3516.CrossRefPubMed

27.

Grant CS, Hay ID, Gough IR, Bergstralh EJ, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104:954–62.PubMed

28.

Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64.PubMedCrossRef

29.

Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63. https://doi.org/10.1210/jcem.86.4.7407.CrossRefPubMed

30.

Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–5. https://doi.org/10.1097/SLA.0000000000000925. discussion 605-7.CrossRefPubMed

31.

Nixon IJ, Palmer FL, Whitcher MM, Shaha AR, Shah JP, Patel SG, Ganly I. Thyroid isthmusectomy for well- differentiated thyroid cancer. Ann Surg Oncol. 2011;18:767–70. https://doi.org/10.1245/s10434-010-1358-8.CrossRefPubMed

32.

Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81–9. https://doi.org/10.1007/s1043-004-1165-1.CrossRefPubMed

33.

Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause- specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645–9. https://doi.org/10.1002/hed.21504.CrossRefPubMed

34.

Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61. https://doi.org/10.1001/archoto.2010.181.CrossRefPubMed

35.

Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Uruno T, Suzuki A, Magoshi S, Akaishi J, Masaki C, Kawano M, Suganuma N, Rino Y, Masuda m, Kameyama K, Takami H, Ito K. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79. https://doi.org/10.1007/s00268-013-2224-1.CrossRefPubMed

36.

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery.1993; 114:1050-5; discussion 1057-8.

37.

Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85. https://doi.org/10.1007/s00268-002-6612.CrossRefPubMed

38.

Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo L. Complications of thyroid Surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg. 2004;28:271–6. https://doi.org/10.1007/s00268-003-6903-1.CrossRefPubMed

39.

Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, Sasai H, Masuoka H, Yabuta T, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A. Incidences of unfavorable events in the management of low-risk Papillary Microcarcinoma of the thyroid by active Surveillance Versus Immediate Surgery. Thyroid. 2016;26:150–5. https://doi.org/10.1089/thy-2015.0313.CrossRefPubMedPubMedCentral

40.

Hartl DM, Schlumberger M. Extent of Thyroidectomy and incidence of morbidity: risk-appropriate treatment. Thyroid Surgery: preventing and managing Complications, 2013. Wiley Online Library.

41.

Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and Surgery in papillary microcarcinoma. Thyroid. 2016;26:144–9.PubMedPubMedCentralCrossRef

42.

Ito Y, Miyauchi A. Active surveillance as first-line management of papillary microcarcinoma. Annu Rev Med. 2019;70:369–79.PubMedCrossRef

43.

Ito Y, Miyauchi A, Kudo T, Oda H, Yamamoto M, Sasai H, Masuoka H, Fukushima M, Higashiyama T, Kihara M, Miya A. Trends in the implementation of active surveillance for low-risk papillary thyroid microcarcinomas at Kuma Hospital: gradual increase and heterogeneity in the acceptance of this new management option. Thyroid. 2018;28:488–95.PubMedPubMedCentralCrossRef

44.

Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381–7. https://doi.org/10.1089/105072503321669875.CrossRefPubMed

45.

Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT. Natural history and Tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143:1015–20.PubMedPubMedCentralCrossRef

46.

Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J. 2009;56:177–92.PubMedCrossRef

47.

Kwon H, Oh HS, Kim M, Park S, Jeon MJ, Kim WG, Kim WB, Shong YK, Song DE, Baek JH, Chung KW, Kim TY. Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea. J Clin Endocrinol Metab. 2017;102:1917–25. https://doi.org/10.1210/jc.2016-4026.CrossRefPubMed

48.

Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 2010;95:4576–83.PubMedCrossRef

49.

Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–31.PubMedCrossRef

50.

Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, Yamada K. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid. 2019;29:59–63. https://doi.org/10.1089/thy.2018.0462.CrossRefPubMed

51.

Smulever A, Pitoia F. Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America. Arch Endocrinol Metab. 2019;63:462–9. https://doi.org/10.20945/2359-3997000000168.CrossRefPubMedPubMedCentral

52.

Rosario PW, Mourão GF, Calsolari MR. Active surveillance in adults with low-risk papillary thyroid Microcarcinomas: a prospective study. Horm Metab Res. 2019;51:703–8. https://doi.org/10.1055/a-1015-6684.CrossRefPubMed

53.

Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V, Viola D, Cappagli V, Valerio L, Giani C, Puleo L, Lorusso L, Piaggi P, Torregrossa L, Basolo F, Vitti P, Tuttle RM, Elisei R. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian Center. J Clin Endocrinol Metab. 2020;105:e172–80. https://doi.org/10.1210/clinem/dgz113.CrossRefPubMed

54.

Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34. https://doi.org/10.1089/thy.2013.0367.CrossRefPubMedPubMedCentral

55.

Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–21. https://doi.org/10.1016/j.ecl.2014.02.010.CrossRefPubMed

56.

Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F. Delayed risk stratification, to include the response to initial treatment (Surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441–6.PubMedCrossRef

57.

Lee YM, Cho JW, Hong SJ, Yoon JH. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. J Surg Oncol. 2018;118:636–43.PubMedCrossRef

58.

Ozkan E, Soydal C, Nak D, Kucuk NO, Kir KM. Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer. Nucl Med Commun. 2017;38:1055–9.PubMedCrossRef

59.

Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid. 2013;23:1401–7.PubMedCrossRef

60.

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.PubMedPubMedCentralCrossRef

61.

Pitoia F, Jerkovich F, Urciuoli C, Schmidt A, Abelleira E, Bueno F, Cross G, Tuttle RM. Implementing the modified 2009 American thyroid Association risk stratification system in thyroid cancer patients with low and intermediate risk of recurrence. Thyroid. 2015;25:1235–42.PubMedCrossRef

62.

Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77:132–8.PubMedCrossRef

60.

-Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid. 2011;21:1317–22.PubMedCrossRef

64.

Sung TY, Cho JW, Lee YM, Lee YH, Kwon H, Jeon MJ, Kim WG, Choi YJ, Song DE, Chung KW, Yoon JH, Hong SJ. Dynamic risk stratification in stage I papillary thyroid cancer patients younger than 45 years of age. Thyroid. 2017;27:1400–7.PubMedCrossRef

65.

Pitoia F, Abelleira E, Tala H, Bueno F, Urciuoli C, Cross G. Biochemical persistence in thyroid cancer: is there anything to worry about? Endocrine. 2014;46:532–7.PubMedCrossRef

66.

Tarasova VD, Tuttle RM. A risk-adapted approach to follow-up in differentiated thyroid cancer. Rambam Maimonides Med J. 2016;7:1–10.CrossRef

67.

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef

68.

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW. Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803.

69.

Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884–7.PubMedCrossRef

70.

Pitoia F, Califano I, Vázquez A, Faure E, Gauna A, Orlandi A, Vanelli A, Novelli JL, Mollerach A, Cabezón C, Fadel A, San Martín A, Figari M. Consenso intersocietario sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Argent Endocrinol Metab. 2014;51:85–118.

71.

Harries V, Wang LY, McGill M, Xu B, Tuttle RM, Wong RJ, Shaha AR, Shah JP, Ghossein R, Patel SG, Ganly I. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? Surgery. 2020;167:10–7.PubMedCrossRef

72.

Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. Risk factors for neck nodal Metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97:1250–7.PubMedCrossRef

73.

Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid Cancer and Radioiodine Remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748–61.PubMedCrossRef

74.

Momesso DP, Vaisman F, Yang SP, Bulzico DA, Corbo R, Vaisman M, Tuttle RM. Dynamic risk stratification in patients with differentiated thyroid Cancer treated without Radioactive Iodine. J Clin Endocrinol Metab. 2016;101:2692–700.PubMedPubMedCentralCrossRef

75.

Park S, Kim WG, Song E, Oh HS, Kim M, Kwon H, Jeon MJ, Kim TY, Shong YK, Kim WB. Dynamic risk stratification for Predicting recurrence in patients with differentiated thyroid Cancer treated without Radioactive iodine remnant ablation therapy. Thyroid. 2017;27:524–30.PubMedCrossRef

76.

Cho JW, Lee YM, Lee YH, Hong SJ, Yoon JH. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. Clin Endocrinol (Oxf). 2018;89:100–9.PubMedCrossRef

77.

Park S, Jeon MJ, Oh HS, Lee YM, Sung TY, Han M, Han JM, Kim TY, Chung KW, Kim WB, Shong YK, Kim WG. Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid Cancer. Thyroid. 2018;28:997–1003.PubMedCrossRef

78.

Ritter A, Mizrachi A, Bachar G, Vainer I, Shimon I, Hirsch D, Diker-Cohen T, Duskin-Bitan H, Robenshtok E. Detecting recurrence following lobectomy for thyroid Cancer: role of Thyroglobulin and Thyroglobulin antibodies. J Clin Endocrinol Metab. 2020;105:dgaa152.PubMedCrossRef

79.

Giovanella L, Ceriani L, Garo ML. Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis. Clin Chem Lab Med. 2022;60:1091–100.PubMedCrossRef

80.

Addasi N, Fingeret A, Goldner W. Hemithyroidectomy for thyroid Cancer: a review. Med (Kaunas). 2020;56:586.

81.

Park JH, Yoon JH. Lobectomy in patients with differentiated thyroid cancer: indications and follow-up. Endocr Relat Cancer. 2019;26:R381–93.PubMedCrossRef

82.

do Prado Padovani R, Chablani SV, Tuttle RM. Radioactive iodine therapy: multiple faces of the same polyhedron. Arch Endocrinol Metab. 2022;66:393–406. https://doi.org/10.20945/2359-3997000000461.CrossRefPubMed

83.

Abelleira E, Peñaloza MA, Jerkovich F, Bueno F, Pitoia F. Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment. Arch Endocrinol Metab 2021; 2359-3997000000355. doi: 10-20945/2359-3997000000355.

84.

Chou R, Dana T, Brent GA, Goldner W, Haymart M, Leung AM, Ringel MD, Sosa JA. Serum thyroglobulin measurement following Surgery without Radioactive Iodine for differentiated thyroid Cancer: a systematic review. Thyroid. 2022;32:613. https://doi.org/10.1089/thy.2021.0666.CrossRefPubMed

85.

Kim M, Han M, Jeon MJ, et al. Impact of delayed radioiodine therapy in intermediate–/high-risk papillary thyroid carci- noma. Clin Endocrinol. 2019;91:449–55.CrossRef

86.

Wang X, Song Q, Xu D, Wang L, Zhang J, Xin S. Effects of timing of initial postoperative radioactive iodine therapy on the outcome of patients with differentiated thyroid cancer. J China Med Univ. 2019;48:359–62.

87.

Ahn J, Jin M, Song E, et al. Clinical outcomes after early and delayed radioiodine remnant ablation in patients with low-risk papillary thyroid carcinoma: propensity score matching analysis. Endocrinol Metab. 2020;35:830–7.CrossRef

88.

Matrone A, Gambale C, Torregrossa L, et al. Delayed 131-I first treatment after Surgery has no impact on the median term out- come of patients with intermediate risk differentiated thyroid cancer. Endocr Pract. 2020;26:58–71.PubMedCrossRef

89.

Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683–9.PubMedCrossRef

90.

Krajewska J, Jarzab M, Kukulska A, et al. Postoperative radioiodine treatment within 9 months from diagnosis significantly reduces the risk of relapse in low risk differentiated thyroid carcinoma. Nucl Med Mol Imaging. 2019;53:320–7.PubMedPubMedCentralCrossRef

91.

Cheng F, Xiao J, Huang F, Shao C, Ding S, Yun C, Jia H. Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: a cohort study and a meta-analysis. Cancer Med. 2022;11:2386–96.PubMedPubMedCentralCrossRef

92.

Lee YM, Cho JW, Hong SJ, Yoon JH. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. J Surg Oncol. 2018; 118: 636–643. doi: 10-1002/jso.25182.

93.

Abelleira E, Bueno F, Smulever A, Pitoia F. Dynamic risk assessment in patients with differentiated thyroid cancer without remnant ablation. Rev Arg End Met. 2017;54:69–75.

94.

Janovsky CC, Maciel RM, Camacho CP, Padovani RP, Nakabashi CC, Yang JH, et al. A prospective study showing an excellent response of patients with low-risk differentiated thyroid Cancer who did not undergo radioiodine remnant ablation after total thyroidectomy. Eur Thyroid J. 2016;5:44–9.PubMedCrossRef

95.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant humanTSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab. 2013;98:2693–700.PubMedCrossRef

96.

Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, et al. Impact on overall survival of radioactive iodine in low risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526–35.PubMedCrossRef

97.

Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98:636–42.PubMedCrossRef

98.

Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural Disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011;75:112–9.PubMedCrossRef

99.

Leboulleux S, Bournaud C, Chougnet CN, Zerdoyd S, Al Ghuzlan AA, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroiz L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Mouellec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. Thyroidectomy without Radioiodine in patients with low-risk thyroid Cancer. N Engl J Med. 2022;386:923–93. https://doi.org/10.1056/NEJMoa2111953.CrossRefPubMed

100.

Ilera V, Califano I, Cavallo A, Faure E, Vázquez A, Pitoia F. Thyroid Department of Sociedad Argentina De Endocrinología Y Metabolismo. Is radioidine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study. Endocrine. 2023;8:606–11. https://doi.org/10.1007/s12020-023-03306-w.CrossRef

101.

Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, Rusu D, Godbert Y, Buffet C, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Toubert ME, Kelly A, Benhamou E, Borget I. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 2018;6(8):618–26.PubMedCrossRef

102.

van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP. Evaluating the 2015 American thyroid Association Risk Stratification System in High-Risk Papillary and follicular thyroid Cancer patients. Thyroid. 2019;29:1073–9.PubMedCrossRef

103.

Pitoia F, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. Endocr Relat Cancer. 2019;26:R553–66.PubMedCrossRef

104.

Yang SP, Bach AM, Tuttle RM, Fish SA. Serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant Disease in low-risk papillary thyroid cancer patients. Endocr Pract. 2015;21:1372–9.PubMedPubMedCentralCrossRef

105.

Peiling Yang S, Bach AM, Tuttle RM, Fish SA. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant Disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. J Clin Endocrinol Metab. 2015;100:1561–7.PubMedPubMedCentralCrossRef

106.

Ahn J, Song E, Kim WG, Kim TY, Kim WB, Shong YK, Jeon MJ. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine. 2020;67:623–9.PubMedCrossRef

107.

Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012;53(5):754 – 64. https://doi.org/10.2967/jnumed.111.104133. PMID: 22550280.

108.

Bueno F, Falcone MGG, Peñaloza MA, Abelleira E, Pitoia F. Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. Endocrine. 2020; 67:387–396. https://doi.org/10.1007/s12020-019-02112-7. Epub 2019 Oct 24. Erratum in: Endocrine. 2020; 70:200–201.

109.

Abelleira E, García Falcone MG, Bueno F, Pitoia F. Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. Endocrinol Diabetes Nutr (Engl Ed). 2020;67:517–24.PubMed

110.

Piccardo A, Trimboli P, Puntoni M, Foppiani L, Treglia G, Naseri M, Bottoni GL, Massollo M, Sola S, Ferrarazzo G, Bruzzone M, Catrambone U, Arlandini A, Paone G, Ceriani L, Cabria M, Giovanella L. Role of 18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk differentiated thyroid Cancer patients. Thyroid. 2019;29:549–56.PubMedCrossRef

111.

Jerkovich F, Abelleira E, Bueno F, Guerrero L, Pitoia F. Active surveillance of small metastatic lymph nodes as an alternative to Surgery in selected patients with low-risk papillary thyroid Cancer: a retrospective cohort study. Thyroid. 2022;32:1178–83.PubMed

112.

Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:2307.PubMedCrossRef

113.

Xing M. Genetic-guided risk assessment and management of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48:109–24.PubMedPubMedCentralCrossRef

114.

Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.PubMedCrossRef

115.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O´Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501. https://doi.org/10.1001/jama.2013.3190.CrossRefPubMedPubMedCentral

116.

Vuong HG, Altibi AMA, Duong UNP, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2017;87:411–7.CrossRef

117.

Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ 3rd, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE. American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. Thyroid. 2015;25:760–8.PubMedPubMedCentralCrossRef

118.

Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. Endocr Pract. 2017;23:979–88.PubMedCrossRef

119.

Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–69.PubMedPubMedCentralCrossRef

Title: Dynamic risk assessment in patients with differentiated thyroid cancer
Authors: Erika Abelleira
Fernando Jerkovich
Publication date: 28-11-2023
Publisher: Springer US
Keywords: Thyroidectomy
Thyroidectomy
Hemithyroidectomy
Hemithyroidectomy
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2024
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-023-09857-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review

Update on anaplastic thyroid carcinoma

The relationship between thyroid and human-associated microbiota: A systematic review of reviews

Thyroid cancer and insulin resistance

Does it work in childhood and adolescence? The predictive role of postoperative/preablative stimulated thyroglobulin levels in paediatric thyroid cancer. A systematic review of the literature

Molecular testing for thyroid nodules: Where are we now?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials